Djvlad
@vladtv·6.4M subscribers·40.2K videos
Martin Shkreli: I Made $60M When My Pharma Company Went Public (Part 5)
Posted
June 23, 2024
Views
102,257
Likes
1,386
Comments
242
Engagement
1.59%
June 23, 2024
102,257
1,386
242
1.59%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
5:00Now PlayingWatch full interviews early, uncensored and adfree as a Member
Watch this Full Interview
--------
Martin Shkreli discussed his financial success when his pharmaceutical company, Retrophin, went public. Shkreli shared an intriguing backstory into the company. Initially a private entity, Retrophin experienced overwhelming investor interest, with demand far exceeding their $40 million target during their Nasdaq IPO. Shkreli recounted a critical moment when Vivek demanded every dollar of his $15 million investment, citing his early faith in Shkreli's vision. Despite fierce competition from other investors, Shkreli honored Vivek's request, a decision he reminisced about with admiration. Retrophin's stock surged from its initial public price of around $3 to as high as $28, contributing to Shkreli’s fortune of approximately $60 million. Despite this financial success, Shkreli’s tenure at the helm was cut short.
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
